| http://www.w3.org/ns/prov#value | - Development of formulations that can be used in young children is a high priority for all promising investigational TB drugs.The magnitude and variability of drug interactions may be expected to be different in pediatric populations than in adults, as expression of key metabolizing enzymes changes as children develop [53], and responses to drugs that inhibit or induce metabolizing enzymes may also
|
